Technical Analysis for EPRSQ - Epirus Biopharm Inc

Grade Last Price % Change Price Change
grade A 0.0035 40.00% 0.0010
EPRSQ closed up 40.0 percent on Tuesday, July 7, 2020, on 18.58 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical EPRSQ trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Older signals for EPRSQ ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company's products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.
Medicine Biotechnology Medical Specialties Drugs Biopharmaceutical Antibodies Alpha Rheumatoid Arthritis Monoclonal Antibodies Inflammatory Diseases Plaque Psoriasis Biosimilar Janssen Biotech Adalimumab Infliximab Psoriatic Arthritis Remicade Tnf Inhibitors

Is EPRSQ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 0.0055
52 Week Low 0.0001
Average Volume 64,299
200-Day Moving Average 0.0022
50-Day Moving Average 0.0027
20-Day Moving Average 0.0028
10-Day Moving Average 0.0029
Average True Range 0.0008
ADX 21.22
+DI 47.9452
-DI 24.6575
Chandelier Exit (Long, 3 ATRs ) 0.0017
Chandelier Exit (Short, 3 ATRs ) 0.0044
Upper Bollinger Band 0.0036
Lower Bollinger Band 0.0020
Percent B (%b) 0.94
BandWidth 57.1429
MACD Line 0.0001
MACD Signal Line 0.0001
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0056
Resistance 3 (R3) 0.0054 0.0044 0.0053
Resistance 2 (R2) 0.0044 0.0039 0.0046 0.0051
Resistance 1 (R1) 0.0040 0.0036 0.0042 0.0042 0.0050
Pivot Point 0.0030 0.0030 0.0032 0.0032 0.0030
Support 1 (S1) 0.0026 0.0025 0.0028 0.0028 0.0020
Support 2 (S2) 0.0016 0.0022 0.0018 0.0019
Support 3 (S3) 0.0012 0.0016 0.0018
Support 4 (S4) 0.0014